YAP1 and cancer: Since YAP upregulation confers a survival dependence in RAS-RAF-MEK inhibitor resistant human cancers (Kapoor et al., 2014; Lin et al., 2015; Shao et al., 2014; Su et al., 2021; Zhang et al., 2014), we hypothesized that WT-CIC represses YAP1 to maintain a drug sensitive state.